Empagliflozin in Patients with Chronic Kidney Disease

Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial

(2022) et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes

(2021) Bertram Pitt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dapagliflozin in Patients with Chronic Kidney Disease

(2020) Hiddo J.L. Heerspink et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

(2020) George L. Bakris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

(2020) David C Wheeler et al.   Lancet Diabetes & Endocrinology

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

(2019) Vlado Perkovic et al.   NEW ENGLAND JOURNAL OF MEDICINE

Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency

(2019) Andrew S. Levey et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Chronic Kidney Disease

(2017) Angela C Webster et al.   LANCET

Analysis of recurrent events with an associated informative dropout time: Application of the joint frailty model

(2016) Jennifer K. Rogers et al.   STATISTICS IN MEDICINE

A New Equation to Estimate Glomerular Filtration Rate

(2013) Andrew S. Levey et al.   ANNALS OF INTERNAL MEDICINE

Chronic kidney disease: global dimension and perspectives

(2013) Vivekanand Jha et al.   LANCET

Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis

(2012) Caroline S Fox et al.   LANCET

Chronic kidney disease

(2011) Andrew S Levey et al.   LANCET